45
Crosslink Therapeutics Inc. raises $4.3M under Reg D
Company raise · Raising · Offering $8M · Sold $4.3M · BOSTON, MA · filed 2025-05-15
40
Crosslink Therapeutics closes $5.5M raise in Boston
Company raise · Closed · BOSTON, MA · Form D filed 2026-10-20
Crosslink Therapeutics Inc., a Delaware-incorporated pharmaceutical company based in Boston, closed a $5.5M offering under Regulation D exemption 6(b) on October 8, 2026. The company sold shares to 8 investors with no placement agent involvement.
operating_company
Why now — by persona
- Executive & technical recruiting:A concrete reason to call this issuer this week, citing the filing. Subscribe to unlock
- B2B software & services sales:A concrete reason to call this issuer this week, citing the filing. Subscribe to unlock
- Commercial banking / treasury:A concrete reason to call this issuer this week, citing the filing. Subscribe to unlock
- D&O and management-liability insurance:A concrete reason to call this issuer this week, citing the filing. Subscribe to unlock
- Outsourced accounting / CFO:A concrete reason to call this issuer this week, citing the filing. Subscribe to unlock
People on the filing
| Ronald D. Seidel, III | Executive Officer, Director |
| Andrew King | Director |
| Lou Tartaglia | Director |
| Rodolfo Chaparro | Director |
| David Fallace | Director |
| Cameron Gallagher | Director |
Signed by Ronald D. Seidel, III, Chief Executive Officer.
Filing contact
The issuer's phone number and address from the filing are shown to subscribers. See plans, or read it on EDGAR.